Clinical trials: Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
Prevalence of heart failure with preserved ejection fraction (HFpEF) continues to increase in the developed world, likely because of the increasing life expectancy and an increasing number of elderly patients.
- Trial name
- EMPATHY-HF (NCT05792059)
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure With Preserved Ejection Fraction
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
- Trial name
- HFpEF-BB (NCT05174351)
- Testing
- beta blocker discontinuation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UConn Health
Left Ventricular Diastolic Function
Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF
This prospective cohort study evaluates the effects of six months of sacubitril/valsartan (ARNI) therapy on left ventricular diastolic function in patients with heart failure with reduced ejection fraction (HFrEF) using…
- Trial name
- NCT07157527
- Volunteers
- 70 people
- Sponsor
- Assiut University
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Use of Advanced Imaging in HFpEF
Heart failure with preserved ejection fraction (HFpEF) causes symptoms of breathlessness and leg swelling. It is associated with significant number of hospital admissions and could lead to the patient's death.
- Trial name
- NCT06905405
- Testing
- Advanced imaging, SGLT-2 inhibitor
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Gall Bladder Pain, Hepatobiliary Iminodiacetic Acid
Ejection Fraction of Normal Gall Bladder on Ultrasonography in Patients With Biliary Colic: Is it a Predictor of Cholecystectomy?
In this study investigators aim to evaluate gallbladder ejection fraction as a predictor for cholecystectomy.
- Conditions
- Gall Bladder Pain, Hepatobiliary Iminodiacetic Acid, Acalculous Cholecystitis
- Trial name
- NCT05587933
- Testing
- cholecystectomy, Antispasmodic
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Myocardial Infarction
Aerobic Interval Training v/s Resistance Interval Training On Ejection Fraction In Stable Post MI Patients
Randomized controlled trial (single blinded) study was conducted on 26 stable Post MI patients according to inclusion and exclusion criteria aged 35 to 65 years.
- Trial name
- NCT03708484
- Testing
- Aerobic Interval Training, Aerobic + Resistive Interval Training
- Where
- Pakistan
- Volunteers
- 26 people
- Sponsor
- Riphah International University
Sodium-GLucose coTransporter-2 Inhibitors, Heart Failure With Reduced Ejection Fraction
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
It is an observational, cohort, prospective, multicentre, Italian, non-profit study, with the aim of evaluating the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and…
- Trial name
- DISCOVERSGLT2i (NCT05344963)
- Testing
- Sodium-GLucose coTransporter-2 inhibitors
- Where
- Italy
- Volunteers
- 503 people
- Sponsor
- Matteo Cameli
Diastolic Dysfunction
Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction
Although half of the patients with HF has normal ejection fraction or slightly altered (HF-PEF) and the prognosis differs little from those with reduced ejection fraction, the pathophysiology of HF-PEF is still poorly understood.
- Trial name
- NCT01896908
- Testing
- Sodium restriction
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Heart Failure With Reduced Ejection Fraction
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05952089
- Testing
- Danicamtiv, Midazolam
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Coronary Microvascular Dysfunction, Heart Failure With Preserved Ejection Fraction (HFpEF)
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
The purpose of this study is to examine small vessel disease (a condition in which the small arteries in the heart become narrowed).
- Trial name
- NCT03876223
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure With Reduced Ejection Fraction, Congestion
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the…
- Trial name
- ERTU-SODIUM (NCT05152940)
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Heart Failure, Congestive, Dyspnea
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Heart failure (HF) is a disease that is caused by a reduced heart muscle function. Reduced heart muscle function can occur as a consequence of reduced pumping activity from a weak heart muscle or because of a stiff heart muscle.
- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Trial name
- NCT00505791
- Testing
- Nesiritide
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
Distribution and Clinical Implication of CMD in Patients With HFpEF Without Significant CAD
To evaluate the incidence of coronary microvascular dysfunction (CMD) and its' prognostic implication in patients who have diagnosed as heart failure with preserved ejection fraction (HFpEF) confirmed by HFA-PEFF scoring system…
- Trial name
- HFpEF-CMD (NCT04788576)
- Testing
- Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Heart Failure, Diastolic, Heart Failure, Systolic
Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients
To better understand the public health prognostic impact of noncardiac chronic illnesses, we explored the attributable risk of noncardiac comorbidities on outcomes between heart failure patients with reduced ejection fraction…
- Trial name
- NCC-HF (NCT02946476)
- Testing
- prognostic impact of non cardiac comorbidities
- Volunteers
- 2,314 people
- Sponsor
- Ospedale Maggiore Di Trieste
Heart Failure, Sarcopenia
The Sarcopenia Study
The goal of this cross-sectional study is to investigate the prevalence of sarcopenia in patients with Heart Failure. The main question it aims to answer is: Whether there is a difference in the prevalence of sarcopenia across…
- Conditions
- Heart Failure, Sarcopenia, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT05888688
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
Use of Beta-agonists in Stable Severe Congestive Heart Failure
The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure
- Trial name
- NCT01447069
- Testing
- Salbutamol
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.